Lentitek
Lentitek specialises in developing manufacturing technologies for lentiviral vectors, which are essential in the delivery of CAR-T cell and gene therapies – breakthrough treatments for cancer and genetic disorders.
Lentitek has raised €830k across 1 funding round from 1 investor, most recently a round in Mar 2025. Based in Edinburgh, UK; active in Healthtech. Data as of 28 Oct 2026.
Edinburgh, UKwww.lentitek.com ↗
Total raised
€830k
€829,639
Funding rounds
1
Investors
1
distinct backers
Active since
2025-03
latest 2025-03
Funding by year
EUR raised per yearLentitek — funding by year — interactive chart.
Data table
| Lentitek — funding by year | |
|---|---|
| 2025 | €830k |
Signals
High confidenceRaise-next likelihood38
base rate 30% for Other
- ▲ In typical raise window
- ▼ Low backer re-investment
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
Funding rounds
1 round| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-03-11 | Other | €830k | Equity Gap | View deal → |